Fig. 4
Adverse events comparative risk overview in the CDK 4/6 inhibitors trials A: Monaleesa 2 trial; B: Palama trials; C: Monarch 3 trial
Fig. 4 | BMC Cancer
Adverse events comparative risk overview in the CDK 4/6 inhibitors trials A: Monaleesa 2 trial; B: Palama trials; C: Monarch 3 trial